Less Ads, More Data, More Tools Register for FREE

Pin to quick picksKGP.L Regulatory News (KGP)

  • There is currently no data for KGP

Interim Management Statement

10 Nov 2014 07:00

RNS Number : 5259W
Kingspan Group PLC
10 November 2014
 

Kingspan Group Plc

Interim Management Statement

 

10 November 2014

 

Kingspan Group plc, the global leader in high performance insulation and building envelopes, today issues the following Interim Management Statement, with trading information for the period from 1 July to 30 September 2014.

 

Sales in the nine month period to 30 September were €1.39bn, up 5% on the prior year (+5% constant currency). A solid sales performance was also recorded in the third quarter with revenue up 7% (+5% constant currency) compared to the same period in 2013.

Insulated Panels revenue in the first nine months increased by 9% (+9% constant currency), and by 8% (+7% constant currency) in the third quarter. The UK continued to perform well with encouraging activity across most building segments. After a sluggish second quarter sales performance, Mainland Europe remained weak through the third quarter reflecting somewhat of an abatement in German market activity. The pace of sales growth in North America improved in the third quarter helped by a strong order book as we entered the second half. Order intake also showed a significant improvement over prior year. Activity in Australasia continued the strong trend evident in the first half.

Insulation Board revenue in the first nine months was up 3% (+1% constant currency) compared with the same period last year, and ahead by 6% in quarter three (+2% constant currency). The UK sales performance was positive through the third quarter, and Mainland European sales were relatively stable overall year on year. Further progress in market conversion was evident in Australia during the third quarter.

Environmental revenue in the first nine months was ahead of last year by 1% (-2% constant currency) and by 3% (-3% constant currency) in the third quarter, continuing on the path of relative stabilisation seen earlier in the year.

Access Floors revenue in the first nine months was 4% behind the same period last year (-4% constant currency). Sales in the third quarter were ahead by 11% (+8% constant currency) with continuing momentum evident in UK office construction activity and an improvement in the US relative to a weak first half.

 Net debt at the end of September 2014 was €107.7m, €39.1m lower than at the same point in 2013. The fourth quarter is a seasonally cash generative period and this would indicate net debt levels by year end in the region of €140m after taking account of the acquisitions of Pactiv Insulation (North America) and PAL (UAE). These insulation board businesses were separately acquired in October for a combined consideration of €77m.The relative optimism that prevailed earlier in the year appears to have waned in recent months, particularly in Europe. Whilst our business continues to perform solidly, we nonetheless are mindful of what are currently more tempered 2015 economic forecasts, and remain focused on driving the Kingspan proposition, whatever the macro climate.

The fourth quarter of 2013 was particularly strong for the Group. Notwithstanding that, and with this seasonally important and often variable period to come, we expect to deliver a full-year trading profit in the region of €144m (+17% versus 2013).

 

For further information contact:

 

Gene Murtagh, Chief Executive Officer Tel: +353 (0) 42 9698000

 

Geoff Doherty, Chief Financial Officer Tel: +353 (0) 42 9698000

 

Douglas Keatinge, Murray Consultants Tel: +353 (0) 1 4980300

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBRBDBGUGBGSR
Date   Source Headline
6th Jan 20215:12 pmRNSHolding(s) in Company
5th Jan 20214:03 pmRNSHolding(s) in Company
4th Jan 202110:00 amRNSBlock listing Interim Review
4th Jan 20219:00 amRNSTotal Voting Rights
17th Dec 20209:00 amRNSDirectorate Change
1st Dec 20204:12 pmRNSTotal Voting Rights
16th Nov 20207:00 amRNSTrading Statement
2nd Nov 20201:04 pmRNSDirector/PDMR Shareholding
2nd Nov 202012:19 pmRNSTotal Voting Rights
15th Oct 20205:04 pmRNSDirector/PDMR Shareholding
14th Oct 20201:05 pmRNSDirector/PDMR Shareholding
1st Oct 202012:42 pmRNSTotal Voting Rights
29th Sep 20202:32 pmRNSDirector/PDMR Shareholding
15th Sep 20207:00 amRNSGreen Private Placement
1st Sep 20203:44 pmRNSTotal Voting Rights
24th Aug 20205:34 pmRNSDirector/PDMR Shareholding
24th Aug 20205:27 pmRNSDirector/PDMR Shareholding
21st Aug 20207:00 amRNSHalf-year Report
1st Jul 20206:17 pmRNSBlock listing Interim Review
1st Jul 202011:27 amRNSTotal Voting Rights
25th Jun 20203:44 pmRNSHolding(s) in Company
17th Jun 20204:51 pmRNSHolding(s) in Company
2nd Jun 20203:00 pmRNSTotal Voting Rights
1st May 20203:20 pmRNSResult of AGM
1st May 20209:45 amRNSTotal Voting Rights
30th Apr 20207:00 amRNSTrading Statement
17th Apr 20204:11 pmRNSHolding(s) in Company
17th Apr 20207:00 amRNSStatement re AGM
14th Apr 202011:41 amRNSHolding(s) in Company
1st Apr 202012:46 pmRNSTotal Voting Rights
30th Mar 202011:37 amRNSHolding(s) in Company
23rd Mar 202011:05 amRNSHolding(s) in Company
19th Mar 202012:00 pmRNSDividend Declaration
18th Mar 20209:15 amRNSHolding(s) in Company
2nd Mar 20202:23 pmRNSTotal Voting Rights
28th Feb 202010:38 amRNSAnnual Financial Report
26th Feb 20204:54 pmRNSDirector/PDMR Shareholding
24th Feb 20205:49 pmRNSHolding(s) in Company
24th Feb 20202:26 pmRNSDirector/PDMR Shareholding
24th Feb 202010:10 amRNSDirector/PDMR Shareholding
21st Feb 20207:00 amRNSFinal Results
20th Jan 20209:50 amRNSHolding(s) in Company
3rd Jan 20205:21 pmRNSHolding(s) in Company
2nd Jan 202011:00 amRNSBlock listing Interim Review
2nd Jan 202010:00 amRNSTotal Voting Rights
17th Dec 201910:45 amRNSDirector/PDMR Shareholding
11th Dec 20195:40 pmRNSDirector/PDMR Shareholding
2nd Dec 20192:58 pmRNSTotal Voting Rights
18th Nov 20197:00 amRNSTrading Update
5th Nov 201912:43 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.